Rituximab in Primary Central Nervous system Lymphoma.A randomized Dutch/Belgian Hemato-Oncology Cooperative Group (HOVON) / Australasian Leukaemia and Lymphoma Group (ALLG) intergroup study

Trial Profile

Rituximab in Primary Central Nervous system Lymphoma.A randomized Dutch/Belgian Hemato-Oncology Cooperative Group (HOVON) / Australasian Leukaemia and Lymphoma Group (ALLG) intergroup study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Rituximab (Primary) ; Carmustine; Cytarabine; Methotrexate; Prednisolone; Prednisolone; Teniposide
  • Indications CNS cancer; Diffuse large B cell lymphoma; Lymphoma
  • Focus Therapeutic Use
  • Acronyms HOVON 105 PCNSL
  • Most Recent Events

    • 02 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 08 Jul 2011 Additional lead trial centres identified as reported by Australian New Zealand Clinical Trials Registry.
    • 08 Jul 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12610000908033).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top